Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 8;37(6):742-745.
doi: 10.1016/j.ccell.2020.05.008. Epub 2020 May 16.

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

Jennifer G Whisenant  1 , Annalisa Trama  2 , Valter Torri  3 , Alessandro De Toma  4 , Giuseppe Viscardi  4 , Alessio Cortellini  5 , Olivier Michielin  6 , Fabrice Barlesi  7 , Anne-Marie C Dingemans  8 , Jan Van Meerbeeck  9 , Vera Pancaldi  10 , Ross A Soo  11 , Natasha B Leighl  12 , Solange Peters  6 , Heather Wakelee  13 , Marina Chiara Garassino  14 , Leora Horn  15
Affiliations

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

Jennifer G Whisenant et al. Cancer Cell. .

Abstract

Prior publications on small subsets of cancer patients infected with SARS CoV-2 have shown an increased risk of mortality compared to the general population. Furthermore, patients with thoracic malignancies are thought to be at particularly high risk given their older age, smoking habits, and pre-existing cardio-pulmonary comorbidities. For this reason, physicians around the world have formed TERAVOLT, a global consortium dedicated to understanding the impact of COVID-19 on patients with thoracic malignancies.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests A.C. reports grants and personal fees from MSD, grants from Roche, grants from BMS, grants and personal fees from Astra-Zeneca, grants from Novartis, and personal fees from Astellas outside the submitted work. S.P. has received education grants, provided consultation, attended advisory board meetings, and provided lectures for Abbvie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, and Vaccibody, from whom she has received honoraria (all fees to institution). H.W. reports a leadership role in IASLC. M.C.G. reports personal fees from Bayer, personal fees and other from Eli Lilly, personal fees from Boehringer Ingelheim, personal fees from Otsuka Pharma, Seattle Genetics and Daiichi Sankyo, personal fees and other from Astra Zeneca, personal fees and other from Novartis, personal fees and other from BMS, personal fees and other from Roche, personal fees and other from Pfizer, personal fees and other from Celgene, personal fees from Incyte, personal fees from Inivata, personal fees from Takeda, other from Tiziana Sciences, other from Clovis, other from GSK, personal fees from Sanofi-Aventis, and other from Spectrum Pharmaceutcials, Blueprint Medicine outside the submitted work. L.H. reports consulting for Astra Zeneca, Incyte, Amgen, EMD Serono, Bayer, Merck, Pfizer, Genentech-Roche, and Xcovery and research funding from Bristol Myers Squibb, Xcovery, and Boehringer Ingelheim. No other authors have disclosures to report.

Figures

Figure 1
Figure 1
Consortium Development Timeline and Global Participation as of May 7, 2020 (A) TERAVOLT was rapidly conceived and executed, with over 400 patients entered into the database within 6 weeks of being active. (B) TERAVOLT includes participation from 28 countries across the world.
See this image and copyright information in PMC

References

    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. - PMC - PubMed
    1. Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z., Zhang Z., You H., Wu M., Zheng Q., et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020 doi: 10.1158/2159-8290.CD-20-0422. Published online April 28, 2020. - DOI - PMC - PubMed
    1. Desai A., Sachdeva S., Parekh T., Desai R. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob. Oncol. 2020;6:557–559. - PMC - PubMed
    1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. - PMC - PubMed
    1. Harris P.A., Taylor R., Minor B.L., Elliott V., Fernandez M., O’Neal L., McLeod L., Delacqua G., Delacqua F., Kirby J. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 2019;95:103208. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources